- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 101,14 | +0,20 % | Gilead's Yeztugo, Eisai's Leqembi Iqlik, Vertex's Journavx among 2025's best inventions: Time | ||
| ZOETIS | 121,98 | +0,38 % | Zoetis Inc.: Zoetis Receives Positive Opinion from CVMP for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs | Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing... ► Artikel lesen | |
| INCYTE | 71,92 | -0,36 % | Data from Incyte's TGFßR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 | Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFßR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally... ► Artikel lesen | |
| AMARIN | 15,500 | -5,49 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| CASSAVA SCIENCES | 3,250 | +0,78 % | Cassava Sciences stock initiated with Buy rating at Lucid Capital Markets | ||
| ACHIEVE LIFE SCIENCES | 2,710 | +1,69 % | ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report | ||
| LIGAND PHARMACEUTICALS | 154,00 | +0,65 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 372,40 | +0,73 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,058 | +0,87 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Enter into Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| TALPHERA | 1,076 | -3,24 % | CorMedix, Inc.: CorMedix Announces Strategic Minority Investment in Talphera | BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 24,400 | 0,00 % | Rigel Pharmaceuticals, Inc.: Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS | Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS
SOUTH SAN FRANCISCO, Calif.... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 78,00 | +0,65 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance | Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of... ► Artikel lesen | |
| SAVARA | 2,980 | +2,76 % | Savara Inc.: Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 | - The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% - - Changes in DLco%, the Primary Endpoint in IMPALA-2, Were... ► Artikel lesen | |
| MOLECULAR TEMPLATES | 0,107 | -0,56 % | NSE - Molecular Templates, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| BIODEXA PHARMACEUTICALS | 9,490 | -12,94 % | Biodexa Pharmaceuticals PLC: Interim results for the six months ended June 30, 2025 | September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen |
Das Unternehmen CORNERSTONE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.